Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
92 participants
INTERVENTIONAL
2022-06-08
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fecal Microbiota Transplantation in Depression
NCT03281044
Estimate the Efficiency of the Association of an Injection of Ketamine and the Venlafaxine in the Severe Major Depressive Disorder for Six Weeks
NCT01557712
Early Effects of Ketamine vs Placebo With Venlafaxine in Severe Depression Patients
NCT06508710
Desvenlafaxine in Opioid-Dependent Patients
NCT02200406
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
NCT00057213
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Increase in the disease prevalence is significantly associated with certain somatic pathologies, including metabolic diseases and functional intestinal disorders. From a therapeutic point of view, approximately 2/3 patients are not in remission after first-line antidepressant treatment. Moreover, 20 to 30% patients resist at all the therapeutic strategies classically proposed in this indication.
The identification of new therapeutic strategies is therefore a major challenge, especially for patients with chronic depression resistant to standard treatments.
Various research studies have shown the involvement of inflammatory mechanisms in depression. Thus, the increase in the disease prevalence is significantly associated with certain somatic pathologies, in particular metabolic diseases, a certain number of which are linked to abnormalities of the intestinal microbiota. In this context, the use of probiotics is interesting because some have antidepressant effects, anti-inflammatory and metabolic properties. However, even if a few studies have shown an antidepressant effect of probiotics with improvement of biological markers of inflammation, it seems that the use of probiotics alone is not sufficient for lasting results on depressive symptoms.
The PROMOOD clinical research project fits into this context. We propose to carry out a multicenter clinical study with the product developed by GYNOV (GynMDD® multitarget compound with 3 active ingredients: an amino acid (L-glutamine), an ingredient purified from a plant extract (Cavacurmine) and a probiotic (Lactobacillus rhamnosus GG). In a preclinical study carried out at the CNRS on 144 mice, a synergy of action between these 3 ingredients was demonstrated on the anxio-depressive systems, resulting in an improvement far greater than the expected effect of composition and comparable to a reference injectable antidepressant (clomipramine).
In theses context, the microbiotherapy proposed in this project is very original because:
* a multi-target approach targeting several mechanisms of action: intestinal permeability, glutamine/glutamate/GABA cycle, insulin resistance, immunomodulation, oxidative stress;
* prospect of an optimization/simplification of care;
* It is very acceptable for patients both from the point of view of tolerance and from the economic point of view.
With a phase II, prospective, multicenter design, this study aims to evaluate the contribution and the tolerance of a multi-targeted microbiotherapy in addition to venlafaxine, in a second-line antidepressant treatment. The treatment will be delivered during 12 weeks.
Baseline measures will be compared to those obtained during the treatement administration (every week) and after the treatment administration (every week for the next 12 weeks).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Microbiotherapy in addition of venlafaxin
Subjects suffering of MDD and treated by venlafaxine in a second-line assigned to start the microbiotherapy during 12 weeks. The microbiotherapy is GynMDD devlopped by Gynov and which is composed by a probiotic associated to polyphenol and an amino acid.
microbiotherapy (GynMDD)
multi-target microbiotherapy add-on venlafaxine
calibration arm
Subjects suffering of MDD and treated by venlafaxine in a second-line assigned to start the placebo therapy during 12 weeks.
placebo
placebo add-on venlafaxine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
microbiotherapy (GynMDD)
multi-target microbiotherapy add-on venlafaxine
placebo
placebo add-on venlafaxine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No response at a first antidepressant
* under venlafaxine
* Signed informed consent form
* Subjects affiliated to or beneficiary from a French social security regime
Exclusion Criteria
* Allergy to one of the compounds of the multi-target probiotic or the placebo
* consuming probiotic-based dietary supplements
* Patient with other psychiatric disorders, except social anxiety disorder, generalized anxiety disorder and nicotine use disorder
* Patient with a serious and/or progressive medical condition, including chronic inflammatory pathologies or autoimmune diseases requiring long-term anti-inflammatory treatment (including corticosteroid therapy) or immunosuppressant.
* Patient with a recent infectious episode likely to require antibiotic therapy.
* Patient presenting with a suicidal risk assessed by the suicide item of the QIDS-C16 scale (score item 12 of the QIDS-C16 \>2)
* Other concomitant antidepressant and/or lithium and/or anti-inflammatory treatment for the duration of the study
* Subject under measure of protection or guardianship of justice
* Subject beneficiary from a legal protection regime
* Subject unlikely to cooperate or low cooperation stated by investigator
* Subject not covered by social security
* Pregnant woman
* Subject being in the exclusion period of another study or provided for by the "National Volunteer File
20 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondation FondaMental
OTHER
GYNOV
INDUSTRY
Centre Hospitalier Universitaire de Besancon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Emmanuel HAFFEN, MD PhD
Role: PRINCIPAL_INVESTIGATOR
CHU de Besançon
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Emmanuel HAFFEN
Besançon, , France
Centre Hospitalier Spécialisé Charles Perrens
Bordeaux, , France
CHU de Clermont-Ferrand
Clermont-Ferrand, , France
Hôpital Henri Mondor / APHP
Créteil, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021/621
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.